Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Lowered to $27.00 at HC Wainwright

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target cut by equities research analysts at HC Wainwright from $30.00 to $27.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 120.41% from the company’s previous close.

Several other research analysts have also commented on EYPT. Guggenheim reiterated a “buy” rating and set a $68.00 price target on shares of Eyepoint Pharmaceuticals in a report on Wednesday, June 24th. Stifel Nicolaus started coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price objective on the stock. Chardan Capital boosted their price objective on shares of Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Cantor Fitzgerald initiated coverage on Eyepoint Pharmaceuticals in a research report on Wednesday, July 8th. They set an “overweight” rating and a $47.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Eyepoint Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $43.38.

Eyepoint Pharmaceuticals Trading Up 5.0%

EYPT stock opened at $12.25 on Thursday. The business’s 50-day moving average is $13.12 and its 200 day moving average is $13.79. Eyepoint Pharmaceuticals has a 12-month low of $9.51 and a 12-month high of $19.11. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -3.50 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). The firm had revenue of $0.51 million during the quarter, compared to analysts’ expectations of $0.39 million. Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. As a group, equities analysts forecast that Eyepoint Pharmaceuticals will post -3.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. KBC Group NV purchased a new stake in shares of Eyepoint Pharmaceuticals during the 1st quarter worth $29,000. Mirae Asset Global Investments Co. Ltd. grew its position in Eyepoint Pharmaceuticals by 51.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after buying an additional 1,358 shares during the period. California State Teachers Retirement System grew its holdings in shares of Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after acquiring an additional 794 shares during the period. Russell Investments Group Ltd. purchased a new stake in Eyepoint Pharmaceuticals during the third quarter worth $76,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Eyepoint Pharmaceuticals in the fourth quarter valued at $98,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.